Filing Details

Accession Number:
0001209191-23-010506
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-17 16:07:38
Reporting Period:
2023-02-15
Accepted Time:
2023-02-17 16:07:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1654151 Deciphera Pharmaceuticals Inc. DCPH () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1325710 L Matthew Sherman C/O Deciphera Pharmaceuticals, Inc.
200 Smith Street
Waltham MA 02451
Evp & Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-15 16,488 $0.00 89,116 No 4 A Direct
Common Stock Disposition 2023-02-16 971 $15.10 88,145 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2023-02-15 65,900 $0.00 65,900 $15.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
65,900 2033-02-14 No 4 A Direct
Footnotes
  1. The reporting person was awarded 16,488 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
  2. This sale was to cover tax liabilities in the vesting of restricted stock.
  3. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.